Housein Wazaz, MD
Gastroenterology · Meriden, CTNPI 1629077714
Payments from drug & device makers
Across 1,135 payments — averaging $95.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$37K
- AbbVie$19K
- Aimmune Therapeutics, Inc.$12K
- Lilly USA, LLC$7K
- Nestle Healthcare Nutrition Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- plus $23K from 35 others
What the payments were for
- Consulting fees$7,1387%
- Speaking & faculty fees$68,75164%
- Travel & lodging$12,17411%
- Food & beverage$20,00718%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,147 in reported general payments places this provider in the 90th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 685 | $586,355 |
| RemicadeInfliximab | 44 | $219,769 |
| ZeposiaOzanimod Hydrochloride | 23 | $206,154 |
| EntyvioVedolizumab | 22 | $195,013 |
| XifaxanRifaximin | 53 | $158,744 |
| IbsrelaTenapanor Hcl | 60 | $139,128 |
| ZenpepLipase/Protease/Amylase | 35 | $76,572 |
| CreonLipase/Protease/Amylase | 55 | $62,057 |
| MotegrityPrucalopride Succinate | 73 | $48,254 |
| TrulancePlecanatide | 67 | $43,248 |
| VoqueznaVonoprazan Fumarate | 55 | $42,540 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 580 | $33,395 |
| Dexlansoprazole DrDexlansoprazole | 109 | $29,515 |
| Pantoprazole Sodium | 2,126 | $27,839 |
| Nitroglycerin | 64 | $27,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Viberzi | $18,740 | $665,745751 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio, Motegrity, Dexilant | $5,048 | $257,494124 claims |
| Johnson & JohnsonRemicade | $1,003 | $219,76944 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $4,777 | $206,15423 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $4,382 | $201,992120 claims |
| Ardelyx, Inc.Ibsrela | $2,892 | $139,12860 claims |
| Aimmune Therapeutics, Inc.Zenpep | $11,570 | $76,57235 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $37,448 | $42,54055 claims |
| GileadVemlidy | $2,046 | $18,43713 claims |
| Redhill Biopharma Inc.Movantik | $253 | $10,58220 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $232 | $7,71141 claims |
| Braintree Laboratories, Inc.Sutab | $129 | $4,28726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 326 gastroenterology providers in Connecticut.
Other gastroenterology in Meriden
- Pramod MistryNew Haven$6M
- Salam ZakkoBristol$2.7M
- Paul FeuerstadtHamden$1.4M
- Angelo ParedesMiddletown$1.3M
- James FrestonFarmington$778K
- Jill GaidosNew Haven$750K
- Houman RezaizadehFarmington$720K
- James BoyerNew Haven$648K
- Guadalupe Garcia TsaoNew Haven$555K
- Loren LaineWest Haven$485K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.